Second reply to the second letter to the editor by Alessandria, Berrino, Malatesta and Donzelli (doi: 10.17179/excli2026-9442). [PDF]
Manzoli L +2 more
europepmc +1 more source
Osmotic Remodeling of Extracellular Vesicles for Precision Nanomedicine
Hypotonic lysis in bidistilled water is used to remodel B lymphocyte–derived extracellular vesicles into cargo‐depleted, structurally preserved nanovesicles. The process reduces intraluminal proteins and nucleic acids, reshapes membrane composition, and enhances tumor‐cell uptake in vitro, while allowing proof‐of‐concept reloading with exogenous agents,
Francesca Susa +18 more
wiley +1 more source
Metabolic Bone Disease in Coeliac Disease: Protecting Bone, Resources, or Both? [PDF]
Tovoli F, Granito A, Zavatta G.
europepmc +1 more source
Liquid‐Processed 2D Aromatic Amorphous Carbon: Defect Engineering and Universal Transport Scaling
Liquid‐processed graphene oxide (GO) thin films undergo a controllable crystalline–to–amorphous transition driven by thermal quenching. By kinetically tuning oxygen‐driven defect formation during reduction, scalable 2D aromatic amorphous carbon phases are stabilized, directly linking nanoscale disorder and defect topology to electronic transport ...
Fabiola Liscio +22 more
wiley +1 more source
Author Correction: Continuous radon monitoring during seven years of volcanic unrest at Campi Flegrei caldera (Italy). [PDF]
Sabbarese C +9 more
europepmc +1 more source
Income Mobility, Automation, and Occupational Licensing
ABSTRACT Technological change has long been tied with distributional concerns due to displacement against certain skills on labor markets. Short‐run dislocations could create scarring in the long run. For example, shifts against less skilled workers with children could limit their ability to improve the inter‐generational income mobility of their ...
Vincent Geloso +2 more
wiley +1 more source
Neutropenia and infectious events during off-label treatment with venetoclax in children with malignant disease: a pharmacovigilance analysis of FDA adverse event reporting system reports. [PDF]
Muratore E +7 more
europepmc +1 more source

